Table 2. Patient characteristics and outcomes of adults initiating antiretroviral therapy by calendar year of initiation and by HIV facility.
| No. of Patients | Median follow-up time days (IQR) | Median ART pickups (IQR) | Age Median(IQR) | Female N (%) | CD4 CountMedian(IQR) | WHO Stage III/IVN (%) | 12 month Mortality (95% CI) | 12 month Lost to Follow-Up (95% CI) | 12 month Retention (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Year of ART Initiation | ||||||||||
| 2007 | 264 | N/A | N/A | 38 (32–46) | 160 (60.1) | 152 (73–237) | 107 (59.4) | 13.8 (9.8–19.1) | 28.0 (22.7–33.5) | 60.2 (54.1–65.8) |
| 2008 | 1058 | N/A | N/A | 38 (31–45) | 662 (62.6) | 190 (95–292) | 332 (48.6) | 5.5 (4.3–7.2) | 18.3 (16.0–20.7) | 76.6 (73.9–79.1) |
| 2009 | 1373 | N/A | N/A | 37 (30–46) | 796 (58.0) | 219 (131–299) | 423 (44.2) | 5.2 (4.1–6.6) | 17.8 (15.8–19.8) | 77.5 (75.2–79.6) |
| 2010 | 1429 | N/A | N/A | 38 (30–46) | 908 (63.5) | 226 (117–321) | 398 (40.7) | 5.4 (4.3–6.7) | 15.3 (13.4–17.2) | 79.7 (77.5–81.7) |
| 2011 | 1989 | N/A | N/A | 37 (30–45) | 1268 (63.8) | 275 (153–372) | 472 (35.9) | 3.5 (2.8–4.5) | 20.7 (19.0–22.5) | 76.2 (74.2–78.0) |
| 2012 | 1841 | N/A | N/A | 37 (30–46) | 1195 (64.9) | 292 (168–437) | 423 (32.3) | 4.3 (3.4–5.4) | 24.3 (22.3–26.3) | 71.9 (69.8–73.9) |
| 2013 | 1764 | N/A | N/A | 36 (29–46) | 1156 (65.5) | 293 (171–418) | 352 (37.9) | 4.4 (3.5–5.6) | 29.6 (27.5–31.7) | 66.7 (64.5–68.9) |
| p = 0.048 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p = 0.081 | ||||
| HIV Facility | ||||||||||
| Clinic 1 | 1514 | 805 (308–1393) | 16 (7–30) | 36 (30–44) | 964 (63.7) | 256 (153–340) | 272 (25.7) | 3.0 (2.2–4.1) | 16.0 (14.1–17.8) | 81.3 (79.2–83.2) |
| Clinic 2 | 1842 | 392 (15–932) | 6 (2–13) | 37 (30–45) | 1265 (68.7) | 308 (192–446) | 793 (59.7) | 1.7 (1.2–2.5) | 37.5 (35.2–40.0) | 61.1 (58.9–63.3) |
| Clinic 3 | 535 | 619 (245–1361) | 11 (4–24) | 38 (31–46) | 361 (67.5) | 168 (134–175) | 60 (20.1) | 2.4 (1.3–4.2) | 23.2 (20.0–26.8) | 74.8 (70.9–78.2) |
| Clinic 4 | 585 | 618 (150–1164) | 11 (4–21) | 38 (30–45) | 378 (64.6) | 358 (219–526) | 106 (22.6) | 7.0 (5.1–9.4) | 18.8 (15.8–22.1) | 74.5 (70.8–77.9) |
| Clinic 5 | 518 | 623 (250–1058) | 15 (7–27) | 35 (29–43) | 330 (63.7) | 285 (204–358) | 33 (12.6) | 1.6 (0.8–3.3) | 25.3 (21.6–29.1) | 73.6 (69.5–77.1) |
| Clinic 6 | 475 | 711 (224–1326) | 13 (6–23) | 37 (31–45) | 288 (60.6) | 237 (124–342) | 148 (49.7) | 5.9 (4.0–8.5) | 13.9 (11.0–17.2) | 80.8 (77.0–84.1) |
| Clinic 7 | 452 | 560 (124–1038) | 6 (3–10) | 42 (34–50) | 226 (50.0) | 168 (64–307) | 103 (47.5) | 6.2 (4.2–9.1) | 31.4 (27.2–35.7) | 63.7 (59.1–68.0) |
| Clinic 8 | 719 | 667 (296–1232) | 16 (8–29) | 36 (29–45) | 439 (61.1) | 270 (124–387) | 139 (30.3) | 6.4 (4.8–8.6) | 13.2 (10.9–15.8) | 80.7 (77.6–83.4) |
| Clinic 9 | 437 | 861 (463–1556) | 18 (10–33) | 37 (30–47) | 283 (64.8) | 199 (73–314) | 182 (63.0) | 7.8 (5.6–10.8) | 5.9 (4.0–8.4) | 86.5 (82.9–89.4) |
| Clinic 10 | 2125 | 610 (161–1249) | 10 (5–18) | 37 (30–47) | 1193 (56.1) | 219 (102–314) | 562 (39.9) | 6.5 (5.5–7.7) | 20.4 (18.7–22.1) | 73.6 (71.7–75.4) |
| Clinic 11 | 516 | 786 (440–1255) | 17 (10–27) | 37 (30–46) | 331 (64.1) | 234 (153–314) | 109 (41.0) | 8.7 (6.5–11.6) | 10.2 (7.8–13.1) | 81.6 (78.0–84.7) |
| p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
P values: Cochrane-Armitage test use for trend in 12-month outcomes. Chi Square for differences in sex and WHO Stage; log-rank test for differences in 12-month outcomes across clinics; Kruskal-Wallis for differences in age and CD4 count.